Raymond James Financial Services Advisors’s Tvardi Therapeutics TVRD Stock Holding History

Raymond James Financial Services Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-283	Closed	-$124K	–	3448
2022 Q1	$124K	Sell	283 -24	-8%	-$9.85K	﹤0.01%	3074
2021 Q4	$135K	Sell	307 -1	-0.3%	-$502	﹤0.01%	3074
2021 Q3	$171K	Buy	308 +3	+1%	+$1.5K	﹤0.01%	3027
2021 Q2	$157K	Sell	305 -12	-4%	-$7.6K	﹤0.01%	3067
2021 Q1	$247K	Sell	317 -2	-0.6%	-$1.37K	﹤0.01%	2761
2020 Q4	$174K	Sell	319 -21	-6%	-$11K	﹤0.01%	2762
2020 Q3	$156K	Buy	340 +4	+1%	+$2.32K	﹤0.01%	2603
2020 Q2	$207K	Buy	336 +12	+4%	+$6.63K	﹤0.01%	2473
2020 Q1	$154K	Buy	+324	New	+$176K	﹤0.01%	2147

Other funds holding TVRD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James Financial Services Advisors's TVRD Position: Q2 2022 in Review

Raymond James Financial Services Advisors sold out of Tvardi Therapeutics (TVRD) in Q2 2022, closing a stake of 283 shares — an estimated $124K sold.

Raymond James Financial Services Advisors first reported a position in TVRD in Q1 2020 and held it in 9 quarters. The position peaked at $247K in Q1 2021. 179 funds tracked by Wall St. Rank hold TVRD as of Q2 2022.

Raymond James Financial Services Advisors reported no remaining Tvardi Therapeutics position as of Q2 2022 after selling out during the quarter.
Raymond James Financial Services Advisors sold 283 Tvardi Therapeutics shares in Q2 2022, an estimated $124K.
Raymond James Financial Services Advisors first reported a position in Tvardi Therapeutics in Q1 2020 and held it in 9 quarters.
Raymond James Financial Services Advisors's Tvardi Therapeutics position peaked at $247K in Q1 2021.
179 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2022.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.